Public diabetes service attenders were more likely to use insulin treatment (71.1% vs. 41.3%, p = 0.001), dipeptidyl peptidase-4 inhibitors (DPP4i) (44.7% vs. 21.3%, p = 0.002), and glucagon-like peptide-1 receptor agonists (GLP-1 RA) (13.2% vs. 2.6%, p = 0.002). The gene discussed is INS; the disease is diabetes mellitus.